Review Article
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
Table 5
Meta-analysis outcome of efficacy comparing daratumumab and HDACi.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HDACi: histone deacetylase inhibitor; PFS: progression-free survival; OS: overall survival; ORR: overall response rate; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease; HR: hazard ratio. Trials included: trial 1 represents Palumbo et al. (2016); trial 2 represents Dimopoulos et al. (2016); trial 3 represents Lonial et al (2015); trial 4 represents Jakubowiak et al. (2016); trial 5 represents San-Miguel et al. (2014); trial 6 represents Dimopoulos et al. (2013). |